Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.

Oncology 2011 14;80(1-2):107-17. Epub 2011 Jun 14.

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Objective: This study compared outcomes between doublet (AP) and triplet (IAP) neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremity.

Methods: A total of 124 patients were enrolled. In the AP group, a doublet regimen of intraarterial cisplatin and intravenous doxorubicin was given to 77 patients from 1991 to 1999. In the IAP group, a triplet regimen of additional intravenous ifosfamide was given to 47 patients from 2000 to 2007. After completion of 3 cycles of chemotherapy, patients underwent surgery. We assessed tumor response according to pathologic tumor necrosis, and treated patients with further adjuvant chemotherapy.

Results: The overall pathologic response was excellent with more than 90% tumor necrosis in 74.8% of patients. Total necrosis of tumors was also found in 46 (37.4%) patients. There was no difference between the 2 groups in pathologic response (75.3 vs. 72.3%; p = 0.52) or other clinicopathologic parameters. There was no difference between the 2 groups in recurrence rate (31.2 vs. 31.9%; p = 0.17) or lung metastasis (28.6 vs. 23.4%; p = 0.53). Moreover, there were no statistical differences in median disease-free survival and overall survival between the groups. There was more hematologic toxicity in the IAP group (neutropenia, p = 0.002; thrombocytopenia, p = 0.001; febrile neutropenia, p < 0.001).

Conclusions: The addition of ifosfamide to doxorubicin and cisplatin in neoadjuvant chemotherapy did not show improved outcomes in this study. Further trials are required to elucidate optimal neoadjuvant chemotherapy and effective salvage regimens.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000327216DOI Listing
September 2011
11 Reads

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
16
difference groups
8
iap group
8
pathologic response
8
doublet triplet
8
tumor necrosis
8
patients
7
chemotherapy
5
total necrosis
4
patients total
4
necrosis tumors
4
chemotherapyresults pathologic
4
addition ifosfamide
4
adjuvant chemotherapyresults
4
0001conclusions addition
4
response excellent
4
patients adjuvant
4
neutropenia 0001conclusions
4
748% patients
4
90% tumor
4

References

(Supplied by CrossRef)

Friedman MA et al.
J Surg Oncol 1972

Eilber F et al.
J Clin Oncol 1987

Ferrari S et al.
Curr Opin Oncol 2007

Chou AJ et al.
Expert Rev Anticancer Ther 2006

Enneking WF et al.
Clin Orthop Relat Res 1980

Pratt CB et al.
Cancer Treat Rep 1987

Goorin AM et al.
J Clin Oncol 2002

Bacci G et al.
J Chemother 2001

Similar Publications